Brief: Bioinvent's Oncolytic Virus BT-001 Shows Promising Antitumor Activity

BioInvent International AB

16/09/2024 11:55

Sept 16 (Reuters) - Bioinvent International AB
 BINV.ST :
    * SAID ON SATURDAY TRANSGENE AND BIOINVENT’S ONCOLYTIC VIRUS
BT-001 SHOWS PROMISING ANTITUMOR ACTIVITY IN ONGOING PHASE I/IIA
TRIAL IN SOLID TUMORS THAT FAILED PREVIOUS TREATMENTS
    * PRELIMINARY DATA PRESENTED AT ESMO 2024 DEMONSTRATE THAT
BT-001
INDUCES TUMOR REGRESSION IN PATIENTS WHO FAILED PREVIOUS
ANTI-PD(L)-1 TREATMENT
    * IN A PATIENT WITH A HEAVILY PRETREATED LEIOMYOSARCOMA,
BT-001
WAS ABLE TO MODULATE THE TUMOR MICROENVIRONMENT, TURNING A
“COLD” TUMOR TO “HOT”, ENHANCING THE POTENTIAL OF T CELL
INFILTRATION AND A SHIFT TO PD(L)-1 POSITIVITY
    * EARLY SIGNS OF EFFICACY WITH CLINICAL RESPONSES OBSERVED
WITH
BT-001 IN COMBINATION WITH KEYTRUDA® (PEMBROLIZUMAB), IN 2 OF 6
PATIENTS WHO FAILED PREVIOUS TREATMENT

        
 Source text for Workspace:  urn:newsml:reuters.com:*:nGNE9Lmfk9
 Further company coverage:  BINV.ST  

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))